Tags

Type your tag names separated by a space and hit enter

Adherence and acceptability of once daily Lamivudine and abacavir in human immunodeficiency virus type-1 infected children.
Pediatr Infect Dis J. 2006 Jun; 25(6):533-7.PI

Abstract

BACKGROUND

Data on adherence to and acceptability of once daily lamivudine and abacavir are few.

METHODS

Twenty-four U.K. human immunodeficiency virus type-1 infected children 2-13 years of age participated in the Pediatric European Network for the Treatment of AIDS (PENTA) 13 single arm, open label pharmacokinetic study of twice (every 12 hours) versus once (every 24 hours) daily lamivudine and abacavir. Caregivers were asked to complete an adherence questionnaire at screening, week 0 (switch once daily to twice daily) and weeks 4, 12 and 24. Acceptability was also assessed at screening and week 24.

RESULTS

Fifteen children were taking lamivudine and abacavir as part of their regimens, 8 lamivudine only and 1 abacavir only. After switching to lamivudine/abacavir every 24 hours, 7 (29%) received once daily regimens for all drugs. Twenty-three (96%) caregivers thought that switching to once daily lamivudine/abacavir would make things a lot/a little easier for their child: 17 (71%) thought it was actually easier after switching. Six mothers with children taking a mixture of twice/once daily drugs changed their mind, whereas all mothers of children on once daily regimens agreed that it was a lot easier. Nonadherence (missing doses in the last 3 days) was reported for 8 of 118 (7%) completed questionnaires; missed doses were reported for every drug in the regimen with reasons such as "not at home," "forgot" or "routine different from normal." However, viral loads in all these children remained <100 copies/mL.

CONCLUSION

Adherence to once daily abacavir/lamivudine was good with no evidence of an association between nonadherence and virologic rebound. Acceptability of once daily drugs was best when the whole regimen was dosed once daily.

Authors+Show Affiliations

LePrevost M
Family Clinic, North West London NHS Trust, London, United Kingdom.
Green H
No affiliation info available
Flynn J
No affiliation info available
Head S
No affiliation info available
Clapson M
No affiliation info available
Lyall H
No affiliation info available
Novelli V
No affiliation info available
Farrelly L
No affiliation info available
Walker AS
No affiliation info available
Burger DM
No affiliation info available
Gibb DM
No affiliation info available
Pediatric European Network for the Treatment of AIDS 13 Study Group
No affiliation info available

MeSH

AdolescentAge FactorsChildChild, PreschoolDideoxynucleosidesDose-Response Relationship, DrugDrug Administration ScheduleDrug Therapy, CombinationFemaleFollow-Up StudiesHIV InfectionsHIV-1HumansLamivudineMalePatient Acceptance of Health CarePatient ComplianceProspective StudiesRisk AssessmentSex FactorsSingle-Blind MethodTreatment OutcomeUnited KingdomViral Load

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16732152

Clinical Trial Links

Pharmacokinetic (PK) Study of Twice Daily vs Once Daily Lamivudine (3TC) and Abacavir (ABC) as Part of Combination Antiretroviral Therapy (ART) in HIV Infected Children

Citation

LePrevost, Marthe, et al. "Adherence and Acceptability of once Daily Lamivudine and Abacavir in Human Immunodeficiency Virus Type-1 Infected Children." The Pediatric Infectious Disease Journal, vol. 25, no. 6, 2006, pp. 533-7.
LePrevost M, Green H, Flynn J, et al. Adherence and acceptability of once daily Lamivudine and abacavir in human immunodeficiency virus type-1 infected children. Pediatr Infect Dis J. 2006;25(6):533-7.
LePrevost, M., Green, H., Flynn, J., Head, S., Clapson, M., Lyall, H., Novelli, V., Farrelly, L., Walker, A. S., Burger, D. M., & Gibb, D. M. (2006). Adherence and acceptability of once daily Lamivudine and abacavir in human immunodeficiency virus type-1 infected children. The Pediatric Infectious Disease Journal, 25(6), 533-7.
LePrevost M, et al. Adherence and Acceptability of once Daily Lamivudine and Abacavir in Human Immunodeficiency Virus Type-1 Infected Children. Pediatr Infect Dis J. 2006;25(6):533-7. PubMed PMID: 16732152.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Adherence and acceptability of once daily Lamivudine and abacavir in human immunodeficiency virus type-1 infected children. AU - LePrevost,Marthe, AU - Green,Hannah, AU - Flynn,Jacquie, AU - Head,Stephen, AU - Clapson,Margaret, AU - Lyall,Hermione, AU - Novelli,Vas, AU - Farrelly,Laura, AU - Walker,A Sarah, AU - Burger,David M, AU - Gibb,Diana M, AU - ,, PY - 2006/5/30/pubmed PY - 2006/7/28/medline PY - 2006/5/30/entrez SP - 533 EP - 7 JF - The Pediatric infectious disease journal JO - Pediatr Infect Dis J VL - 25 IS - 6 N2 - BACKGROUND: Data on adherence to and acceptability of once daily lamivudine and abacavir are few. METHODS: Twenty-four U.K. human immunodeficiency virus type-1 infected children 2-13 years of age participated in the Pediatric European Network for the Treatment of AIDS (PENTA) 13 single arm, open label pharmacokinetic study of twice (every 12 hours) versus once (every 24 hours) daily lamivudine and abacavir. Caregivers were asked to complete an adherence questionnaire at screening, week 0 (switch once daily to twice daily) and weeks 4, 12 and 24. Acceptability was also assessed at screening and week 24. RESULTS: Fifteen children were taking lamivudine and abacavir as part of their regimens, 8 lamivudine only and 1 abacavir only. After switching to lamivudine/abacavir every 24 hours, 7 (29%) received once daily regimens for all drugs. Twenty-three (96%) caregivers thought that switching to once daily lamivudine/abacavir would make things a lot/a little easier for their child: 17 (71%) thought it was actually easier after switching. Six mothers with children taking a mixture of twice/once daily drugs changed their mind, whereas all mothers of children on once daily regimens agreed that it was a lot easier. Nonadherence (missing doses in the last 3 days) was reported for 8 of 118 (7%) completed questionnaires; missed doses were reported for every drug in the regimen with reasons such as "not at home," "forgot" or "routine different from normal." However, viral loads in all these children remained <100 copies/mL. CONCLUSION: Adherence to once daily abacavir/lamivudine was good with no evidence of an association between nonadherence and virologic rebound. Acceptability of once daily drugs was best when the whole regimen was dosed once daily. SN - 0891-3668 UR - https://www.unboundmedicine.com/medline/citation/16732152/abstract/Adherence_and_Acceptability_of_Once_Daily_Lamivudine_and_Abacavir_in_Human_Immunodeficiency_Virus_Type_1_Infected_Children DB - PRIME DP - Unbound Medicine ER -
Grapherence [↓11]

Related Citations

More